

Resource Summary Report

Generated by [kravitz2](#) on Sep 6, 2026

CD4-FITC, mouse

RRID:AB_2659902

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-102-541, RRID:AB_2659902

Antibody Information

URL: http://antibodyregistry.org/AB_2659902

Proper Citation: Miltenyi Biotec Cat# 130-102-541, RRID:AB_2659902

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Discontinued: 1-2019; Target Distribution dendritic cells, granulocytes, Langerhans cells, lymphocytes, macrophages, monocytes, neutrophils, T cells, T helper cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:30 µg in 1 mL

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-819. (RRID:AB_2752205).

Antibody Name: CD4-FITC, mouse

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: GK1.5

Antibody ID: AB_2659902

Vendor: Miltenyi Biotec

Catalog Number: 130-102-541

Record Creation Time: 20231110T034401+0000

Record Last Update: 20260831T231345+0000

Ratings and Alerts

No rating or validation information has been found for CD4-FITC, mouse.

Warning: Discontinued: 2021

Discontinued: 1-2019; Target Distribution dendritic cells, granulocytes, Langerhans cells, lymphocytes, macrophages, monocytes, neutrophils, T cells, T helper cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:30 µg in 1 mL
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-819. (RRID:AB_2752205).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Krug A, et al. (2024) Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. Journal of experimental & clinical cancer research : CR, 43(1), 43.

Calvani M, et al. (2019) ?3 -Adrenoceptor as a potential immuno-suppressor agent in melanoma. British journal of pharmacology, 176(14), 2509.